spec sheet10 rows
varenicline (chantix/champix) is a cytisine-derived nicotinic partial agonist and a first-line smoking-cessation drug; a high-affinity partial agonist at alpha4beta2 (its core mechanism), full agonist at alpha7, partial at alpha3beta4, and only a weak partial agonist at the alpha6beta2* dopamine-terminal receptors that gate nicotine reward; effective for quitting, with nausea as the main trade-off.
- one of the most effective single-agent smoking-cessation medicines; first-line in guidelines
- dual action: partial agonism relieves craving/withdrawal while occupancy blocks nicotine's full reward
- weakly engages the alpha6beta2* dopamine-terminal fraction that gates nicotine reward, on top of its core alpha4beta2 action
- modestly reduces alcohol consumption (via alpha4* nAChRs) in trials and animal models
- large-scale safety data (EAGLES) substantially reassured on earlier neuropsychiatric concerns
Mechanism
varenicline is a small-molecule partial built from the scaffold of the plant alkaloid cytisine, and its clinical logic is elegant: partially activate the receptors nicotine targets so cravings and withdrawal ease, while occupying those receptors so that inhaled nicotine can no longer deliver a full reward. its functional pharmacology across subtypes is well characterized. according to pubmed, mihalak et al found it is a potent partial agonist at the alpha4beta2 subtype (ec50 around 2.3 micromolar, roughly 13% of 's efficacy, with sub-nanomolar binding affinity), a weak partial agonist at alpha3beta2 and at alpha6-containing receptors (both under 10% efficacy), a partial agonist at the ganglionic alpha3beta4 subtype (about 75% efficacy), and, unexpectedly, a full agonist at the homomeric alpha7 receptor (ec50 about 18 micromolar, 93% efficacy) (doi 10.1124/mol.106.025130). the alpha4beta2 partial agonism is regarded as the core cessation mechanism, but the alpha6 angle is what puts varenicline in this class: alpha6beta2* receptors sit presynaptically on dopamine terminals and gate the reward-relevant fraction of nicotine-evoked dopamine, so even weak partial agonism there contributes to blunting nicotine's reinforcing punch. functional evidence supports the alpha6 involvement; in ventral tegmental slices, varenicline (like the alpha6-selective toxin alpha-conotoxin mii) blocked the enhancement of -receptor function produced by combined nicotine and ethanol (engle et al 2014, doi 10.1016/j.neuropharm.2014.11.014). varenicline also reduces alcohol consumption, but that effect maps onto alpha4* rather than alpha6 receptors; hendrickson et al showed it depends on alpha4* nachrs in the posterior ventral tegmental area, disappearing in alpha4 knockouts and amplifying in alpha4-hypersensitive mice (doi 10.1523/jneurosci.2601-10.2010). clinically it is one of the most effective cessation monotherapies and is first-line in guidelines; brunzell et al frame it as the fda-approved proof that beta2* partial agonism works, while noting that alpha6beta2*-selective agents could someday refine the approach because of their far more restricted, catecholamine-specific localization (doi 10.1111/nyas.12421). the main downside is tolerability, chiefly nausea (plausibly linked to alpha3beta4 activity) and vivid dreams, plus a historical neuropsychiatric-safety debate that the large eagles trial substantially eased. it is a targeted prescription cessation drug, not a .
receptor fingerprint
Alpha4beta2 (a4b2 nAChR)high-affinity partial agonist
Alpha7 (a7)full agonist
Alpha3beta4 (a3b4)partial agonist
Alpha6beta2* (a6-containing)weak partial agonist
Alpha3beta2 (a3b2)weak partial agonist
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
Varenicline's most common adverse effect is nausea, affecting roughly 30 to 40 percent of users (usually mild and dose-related), alongside frequent insomnia, vivid or abnormal dreams, headache, and constipation. It has historically carried warnings about neuropsychiatric events including depressed mood, agitation, behavioral changes, and suicidal ideation; the large EAGLES trial did not confirm a significant excess risk versus placebo/patch, leading the FDA to remove the boxed warning, but patients and caregivers are still advised to watch for mood or behavior changes.
A small increased risk of cardiovascular events (such as myocardial infarction) has been flagged, mainly in patients with pre-existing cardiovascular disease, though absolute rates are low. Rare but serious reports include seizures, angioedema/serious skin reactions, and worsened effects of alcohol; caution is warranted in renal impairment where clearance is reduced. Note that some generic varenicline supplies were subject to recalls over nitrosamine (NDMA) impurity concerns.
Interactionsdocumented pairs only, not exhaustive
Varenicline is barely metabolized; roughly 90 percent of a dose leaves in the urine unchanged, which spares it from cytochrome interactions almost entirely. Formal studies with digoxin, warfarin, bupropion, transdermal nicotine and metformin found nothing clinically meaningful.
The exceptions involve transport and pharmacodynamics. Cimetidine, an inhibitor of the renal organic cation transporter OCT2, raised varenicline exposure by about 29 percent by slowing renal clearance, an effect that counts for more in reduced kidney function. Alcohol is the interaction with real consequences: some people experience amplified intoxication on varenicline, occasionally with aggression or amnesia, and the label carries a warning to that effect. Adding nicotine replacement did not change nicotine levels but roughly doubled nausea, headache, vomiting and dizziness, and a third of participants stopped early.
One indirect effect gets missed. Tobacco smoke induces CYP1A2, so quitting successfully raises levels of clozapine, olanzapine, theophylline and caffeine; that change comes from stopping smoking, not from varenicline.
Checking a whole stack? Run it through interactions + stacks.
Subjective profileweighing the evidence above
Among the most effective single medicines available for quitting smoking, and the large EAGLES trial substantially settled the older neuropsychiatric worry. Nausea affects roughly a third of users and is the usual reason people abandon it; the week-long titration exists for precisely that.
Resources
This entry is here for reference.
Research
- 2006first citedVarenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic…
- 2015most recentNicotine and ethanol cooperate to enhance ventral tegmental area AMPA receptor function via α6-…
- 1.Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors
- 2.Diverse strategies targeting α7 homomeric and α6β2* heteromeric nicotinic acetylcholine receptors for smoking cessation.
- 3.Activation of alpha4* nAChRs is necessary and sufficient for varenicline-induced reduction of alcohol consumption
- 4.Nicotine and ethanol cooperate to enhance ventral tegmental area AMPA receptor function via α6-containing nicotinic receptors.
- 5.Nicotinic receptor antagonists as treatments for nicotine abuse.
5 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
what is varenicline?
it's the smoking-cessation drug sold as chantix (us) and champix (elsewhere), designed around the structure of the plant alkaloid cytisine. it's a nicotinic-receptor partial agonist: it binds the same receptors nicotine does but activates them only partway, so it simultaneously takes the edge off cravings and withdrawal (the partial-agonist part) while blocking nicotine from delivering its full dopamine hit (the competition part). it's one of the most effective single-agent cessation medicines available.
which receptors does it actually hit?
it's not a clean single-target drug. according to pubmed, mihalak et al measured its functional profile: a potent partial agonist at alpha4beta2 (ec50 ~2.3 um, ~13% efficacy), a weak partial agonist at alpha3beta2 and alpha6-containing receptors (under 10% efficacy), a partial agonist at alpha3beta4 (~75% efficacy), and, surprisingly, a full agonist at alpha7 (ec50 ~18 um, ~93% efficacy) (doi 10.1124/mol.106.025130). the alpha4beta2 action is considered the core cessation mechanism.
does its alpha6 activity matter?
it's a real but secondary part of the story. alpha6beta2* receptors sit on dopamine terminals and gate the reward-relevant fraction of nicotine's dopamine release, so a drug that even weakly partial-agonizes them can help dampen nicotine reward. varenicline's alpha6 effect is weak (under 10% efficacy) but functionally visible: in ventral tegmental slices, varenicline blocked the nicotine-plus-ethanol enhancement of ampa function alongside the alpha6-selective toxin alpha-conotoxin mii, implicating alpha6* receptors (engle et al 2014, doi 10.1016/j.neuropharm.2014.11.014). still, the bulk of its clinical effect is attributed to alpha4beta2.
how well does it work for quitting smoking?
it's among the most effective monotherapies; large trials and meta-analyses consistently put it ahead of placebo and bupropion, and it's a first-line agent in cessation guidelines. brunzell et al's review frames varenicline as the fda-approved proof-of-concept that partial agonism of beta2* nicotinic receptors works for cessation, while arguing alpha6b2*-selective agents could refine the approach (doi 10.1111/nyas.12421). the honest caveat is that even on varenicline most quit attempts still fail; it improves the odds, it doesn't guarantee success.
does it also cut alcohol use?
there's real evidence it nudges alcohol consumption down, and the mechanism is instructive. hendrickson et al showed varenicline's reduction of alcohol drinking in mice required alpha4* nicotinic receptors; it worked in wild-type mice, failed in alpha4 knockouts, and low doses became powerful in alpha4-hypersensitive mice, with the ventral tegmental area as the key site (doi 10.1523/jneurosci.2601-10.2010). so its anti-alcohol effect leans on alpha4*, while its reward-blunting also touches alpha6* dopamine terminals.
why does it make people nauseous?
nausea is the most common side effect, reported by a large minority of users, and its partial agonism at the ganglionic alpha3beta4 subtype (~75% efficacy) is a plausible contributor since those receptors sit in autonomic ganglia and the gut-brain axis. taking it with food and titrating the dose up slowly over the first week helps. other reported effects include vivid or abnormal dreams and, historically, neuropsychiatric warnings; the large eagles trial later substantially reassured on the psychiatric-safety question.
how is it different from just using nicotine patches?
nicotine replacement gives you a cleaner, slower nicotine that still fully activates your receptors; varenicline instead sits on the receptor as a partial agonist, so it both provides some relief and physically blocks inhaled nicotine from delivering a full reward if you slip and smoke. that dual 'agonist-and-blocker' behavior is why it tends to outperform nicotine replacement in head-to-head data, though it comes with more side effects.
is it a nootropic?
not really, and it shouldn't be framed as one. it's a prescription cessation drug with a specific job. its alpha7 full-agonism and alpha4beta2 engagement have prompted occasional cognitive research, but there's no good case for taking varenicline for general brain enhancement, and the nausea and neuropsychiatric-monitoring history make casual use a bad idea. it belongs to people trying to quit smoking, under medical supervision.